Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02271230 · ClinicalTrials.gov registry record · Phase 3
Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure
A Phase 3 study of Heart Failure, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 25,871
- Enrollment target
- 1
- Study location
NCT02271230: Completed Phase 3 study of Heart Failure, sponsored by Brigham and Women's Hospital.
NCT02271230 is a Phase 3 study of Heart Failure that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 25,871 participants, above the 1,984-participant average among 397 other Heart Failure trials with a reported enrollment target (1204% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02271230, a Phase 3 study of Heart Failure, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25,871 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine whether an intervention with vitamin D or fish oil supplements can reduce the risk of heart failure among adult men and women during a follow up period of up to five years (starting from the time of randomization into the parent VITAL trial). The investigators hypotheses are that both vitamin D and fish oil supplements will each reduce the risk of heart failure.
Primary Outcome
We will consider any hospitalization for heart failure among participants enrolled in the parent VITAL trial for this ancillary study. Incident heart failure are initially captured through annual questionnaires with subsequent validation by a team of physicians with expertise in cardiovascular medicine and epidemiology. We excluded 36 participants with prevalent heart failure at the time of randomization for the primary analysis.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Vitamin D and fish oil
- DIETARY_SUPPLEMENT Fish oil (EPA/DHA) alone
- DRUG Vitamin D alone
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,871 participants |
| Start Date | 2014-08 |
| Est. Completion | 2019-12 |
| Phase | Phase 3 |
What the finished NCT02271230 record still lists
NCT02271230 is an interventional study that assigns participants to a tested intervention. Its 25,871 participants enrollment target places it among the larger protocols in the corpus, above the 1,984-participant average among 397 other Heart Failure trials with a reported enrollment target (1204% higher).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02271230 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02271230 about?
NCT02271230 is a clinical study titled "Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure". This study will examine whether an intervention with vitamin D or fish oil supplements can reduce the risk of heart failure among adult men and women during a follow up period of up to five years (starting from the time of randomization into the parent VITAL trial). The investigators hypotheses are ...
What is the current status of trial NCT02271230?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25,871 participants. The study started on 2014-08. Estimated completion is 2019-12.
What conditions does trial NCT02271230 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT02271230?
The interventions under investigation include: Placebo (OTHER), Vitamin D and fish oil (DRUG), Fish oil (EPA/DHA) alone (DIETARY_SUPPLEMENT), Vitamin D alone (DRUG).
Who is sponsoring clinical trial NCT02271230?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02271230 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02271230's enrollment target sits among peer trials
25,871 7th of 397 higher than 391 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07300839 · 25,500 participants · Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
- NCT03175302 · 25,240 participants
PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia